Log in
H

Hillhouse

HHLR Advisors · Investor
1Y performance ⓘ
−14%
AUM (13F)
$1.7B
# of Holdings
37
3Y performance ⓘ
+17%
vs S&P 500 ⓘ
−47%
Updated
Mar 31

Hillhouse's HHLR Advisors holds 37 U.S.-equity positions worth $1.7B (SEC 13F, Q1 2026). Top positions: Pdd Holdings Inc 25.4%, Alibaba Group Hldg Ltd 18.4%, Beone Medicines Ltd 18.4%. 13F-replication return is +17% over 3 years (-47 pts vs the S&P 500) — a replicated, non-audited figure.

Holdings

Stock% of portfolio SharesValue Latest activityAvg buy price Current priceDate
PDD Pdd Holdings Inc 25.4% 4.2M $426M ▼ 61% (−6.6M) $113.77 $88.56 (−22%) 2026-03-31
BABA Alibaba Group Hldg Ltd 18.4% 2.5M $308M ▼ 55% (−3.0M) $146.39 $122.25 (−16%) 2026-03-31
ONC Beone Medicines Ltd 18.4% 1.0M $307M $272.17 $316.01 (+16%) 2026-03-31
FUTU Futu Hldgs Ltd 11.6% 1.4M $194M ▼ 13% (−211K) $95.15 $105.12 (+10%) 2026-03-31
LEGN Legend Biotech Corp 6.5% 6.0M $108M $51.64 $18.55 (−64%) 2026-03-31
AVBP ArriVent BioPharma, Inc. Common Stock 5.4% 3.9M $91M $17.95 $29.82 (+66%) 2026-03-31
BEKE Ke Hldgs Inc 3.8% 4.2M $63M $18.44 $16.95 (−8%) 2026-03-31
CWAN Clearwater Analytics Holdings, Inc. 1.9% 1.4M $32M $21.93 (+8%) 2026-03-31
CTKB Cytek Biosciences, Inc. Common Stock 1.7% 6.7M $29M $9.19 $4.22 (−54%) 2026-03-31
MRVL Marvell Technology, Inc. Common Stock 1.0% 171K $17M NEW (+171K) $89.25 $187.56 (+110%) 2026-03-31
YSG Yatsen Hldg Ltd 0.9% 4.9M $15M $2.11 $3.43 (+63%) 2026-03-31
NBP Novabridge Biosciences 0.9% 6.0M $15M $3.98 $1.60 (−60%) 2026-03-31
MAZE Maze Therapeutics, Inc. Common Stock 0.7% 366K $11M ▼ 20% (−92K) $11.01 $26.92 (+145%) 2026-03-31
CTNM Contineum Therapeutics, Inc. Class A Common Stock 0.5% 669K $9M $17.61 $15.49 (−12%) 2026-03-31
API Agora Inc 0.4% 2.1M $7M $4.16 $4.00 (−4%) 2026-03-31
BULL Webull Corporation Class A Ordinary Shares 0.4% 1.5M $7M ▼ 75% (−4.5M) $11.96 $7.06 (−41%) 2026-03-31
TSM Taiwan Semiconductor Manufac 0.3% 16K $5M ▲ 37% (+4K) $215.31 $404.25 (+88%) 2026-03-31
SGMT Sagimet Biosciences Inc. Series A Common Stock 0.2% 725K $4M $8.80 $7.11 (−19%) 2026-03-31
TUYA Tuya Inc 0.2% 1.6M $4M $1.89 $1.68 (−11%) 2026-03-31
GE GE Aerospace 0.2% 10K $3M $207.40 $360.07 (+74%) 2026-03-31
VIPS Vipshop Hldgs Ltd 0.1% 125K $2M NEW (+125K) $13.20 $15.34 (+16%) 2026-03-31
MOGU Mogu Inc 0.1% 848K $2M $3.25 $2.02 (−38%) 2026-03-31
GOSS Gossamer Bio, Inc. Common Stock 0.1% 5.0M $2M $1.26 $0.17 (−87%) 2026-03-31
INTC Intel Corp 0.1% 29K $1M NEW (+29K) $44.13 $90.20 (+104%) 2026-03-31
PACB Pacific Biosciences of California, Inc. 0.1% 919K $1M $8.35 $1.40 (−83%) 2026-03-31
EQX Equinox Gold Corp. 0.1% 80K $1M $11.22 $8.95 (−20%) 2026-03-31
NVDA NVIDIA CORP 0.1% 7K $1M NEW (+7K) $90.36 $200.75 (+122%) 2026-03-31
LITE Lumentum Holdings Inc. Common Stock 0.1% 2K $1M NEW (+2K) $702.76 $713.94 (+2%) 2026-03-31
GLW Corning Incorporated 0.1% 8K $1M NEW (+8K) $135.97 $138.25 (+2%) 2026-03-31
B Barrick Mining Corporation 0.1% 25K $1M $32.77 $36.73 (+12%) 2026-03-31
COHR Coherent Corp. 0.1% 4K $1M NEW (+4K) $238.21 $262.89 (+10%) 2026-03-31
DDL Dingdong Cayman Ltd 0.1% 354K $911K NEW (+354K) $2.57 $2.57 (+0%) 2026-03-31
AXIA Centrais Elet Bras Sa 0.0% 63K $712K ▼ 35% (−34K) $9.16 $10.47 (+14%) 2026-03-31
EWW Ishares Inc 0.0% 9K $662K NEW (+9K) $75.23 $76.81 (+2%) 2026-03-31
ALGS Aligos Therapeutics, Inc. Common Stock 0.0% 76K $567K $8.66 $4.23 (−51%) 2026-03-31
VNET Vnet Group Inc 0.0% 65K $546K ▲ 23% (+12K) $8.45 $7.17 (−15%) 2026-03-31
UXIN Uxin Ltd 0.0% 19K $59K $2.24 $1.39 (−38%) 2026-03-31
Related
PDD stockBABA stockONC stockFUTU stockAll hedge funds
FAQ

What are Hillhouse's largest holdings?

As of the latest 13F: Pdd Holdings Inc 25.4%, Alibaba Group Hldg Ltd 18.4%, Beone Medicines Ltd 18.4%, Futu Hldgs Ltd 11.6%, Legend Biotech Corp 6.5%.

How big is HHLR Advisors's 13F portfolio?

$1.7B across 37 disclosed U.S.-equity positions.

What is Hillhouse's 3-year performance?

+17% (13F-replication, price return), -47 pts vs the S&P 500. Not an audited fund return.

Where does this data come from?

U.S. SEC Form 13F-HR institutional holdings filings.

Sourced from SEC Form 13F-HR filings · Not investment advice
SEC EDGAR 13F
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.

Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.